Obesity/Overweight – Landscape & Forecast – Disease Landscape & Forecast
Obesity is a significant and growing public health concern in the G7 countries. The body of evidence highlighting the medical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, approved drugs are scarce compared with other chronic metabolic diseases, especially in Europe and Japan. However, the development pipeline is strengthening with novel agents that promise to address some of the limitations of current treatments. There is a huge market opportunity for antiobesity drugs that elicit greater and sustained weight loss and are safe, well tolerated, and affordable. However, given the prevalence of obesity, even if such agents are developed and approved, payers will likely need to restrict their access to limit the strain on finite healthcare budgets.
Questions answered:
- Which metabolic and central pathways have high potential as drug targets?
- What is the prevalence of obesity in the major pharmaceutical markets under study?
- How is obesity currently treated? What do experts think about Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) as treatments for obese / overweight patients?
- What is the current level of unmet need according to obesity experts? How will this need be addressed during the 2022-2032 forecast period?
- What is the commercial potential of emerging therapies? How do leaders in the field of obesity treatment rate these drug candidates?
- How will the obesity therapy market evolve over the next 10 years?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 19 country-specific interviews with thought-leading endocrinologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Prevalence of obesity and drug-treatable overweight by country, including diagnosed and drug-treated populations.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key obesity therapies through 2032, segmented by brands / generics and epidemiological subpopulations.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold. Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Obesity/Overweight - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for obesity / overweight?
- What factors are constraining the market for obesity / overweight?
- Patient share by drug class for obesity in the major markets: 2022-2032
- Total obesity sales by drug class in the major markets: 2022-2032
- Sales by obese and drug-eligible overweight subpopulations in the major markets: 2022-2032
- Drug-class-specific trends
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Carles Recasens-Alvarez, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematology. Prior to joining Clarivate, Dr. Recasens-Alvarez was a postdoctoral researcher in the laboratory of Jean-Paul Vincent at the Francis Crick Institute (London), where he investigated the role of protein misfolding and cellular stress in the etiology of ribosomopathies and lead-authored a manuscript. For his doctoral research, he studied the role of cell cycle and apoptosis in development in the laboratory of Professor Marco Milan at the Institute for Research in Biomedicine (Barcelona). He holds a Ph.D. and an M.Sc. in genetics, both from the University of Barcelona, and a B.Sc. in biology from the Autonomous University of Barcelona.